Source-grounded facts extracted from Vaxcyte, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
John Markels was appointed as Director at Vaxcyte, Inc..
“Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026.”
Heath Lukatch retired as Director at Vaxcyte, Inc..
“On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026.”
Moncef Slaoui was appointed as Class II Director at Vaxcyte, Inc..
“On June 17, 2026, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Moncef Slaoui to the Board as a Class II director, which appointment became effective immediately.”
Jacks Lee retired as Director at Vaxcyte, Inc..
“On June 17, 2026, Jacks Lee notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of June 17, 2026.”
Vaxcyte, Inc. shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers at the 2026-06-15 meeting.
“3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers. The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated: For Against Abstain Broker Non-Votes 130,011,017 2,755,868 247,195 4,354,403”
Vaxcyte, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-15 meeting.
“2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain 137,230,032 137,589 862”
Vaxcyte, Inc. shareholders approved Election of three Class III directors to serve until the Company's 2029 Annual Meeting of Stockholders at the 2026-06-15 meeting.
“1. The election of three nominees to serve as Class III directors until the Company’s 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. The following three Class III directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Olivier Brandicourt, M.D. 116,370,183 16,643,897 4,354,403 Halley Gilbert, J.D. 114,704,274 18,309,806 4,354,403 Grant Pickering, M.B.A. 132,112,840 901,240 4,354,403”
Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 6, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Dr. Olivier Brandicourt was appointed as Director at Vaxcyte, Inc..
“On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.”
John P. Furey was appointed as Class II director at Vaxcyte, Inc..
“the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed John P. Furey to the Board as a Class II director, which appointment became effective on July 2, 2024.”
Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2024.
“Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.”
Vaxcyte, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.”
Jacks Lee was appointed as Class II Director at Vaxcyte, Inc..
“appointed Jacks Lee to the Board as a Class II director”
Vaxcyte, Inc. entered into Manufacturing Rights Agreement with Sutro Biopharma, Inc. valued at $50 million (effective 2023-11-21).
“(“Vaxcyte”) entered into an option grant agreement (the “Option Agreement”) with Sutro Biopharma, Inc. (“Sutro,” and together with Vaxcyte, the “Companies”), pursuant to which Vaxcyte acquired from Sutro (i) authorization to enter into an agreement with an independent alternate contract manufacturing organization (“CMO”) to directly source Sutro’s cell-free extract (“Extract”), allowing Vaxcyte to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source Extract from certain CMOs and the right to independently develop and make improvements to Extract (including the right to make improvements to the Extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions (the “Option”
Vaxcyte, Inc. entered into Commercial Manufacturing and Supply Agreement with Lonza Ltd (effective 2023-10-13).
“On October 13, 2023 (the “Effective Date”), Vaxcyte Switzerland GmbH (“Vaxcyte GmbH”), a Swiss limited liability company that, as of such date, was in the process of being formed by Vaxcyte, Inc. (“Vaxcyte”) (as a wholly-owned subsidiary of Vaxcyte), entered into a pre-commercial services and commercial manufacturing supply agreement (the “Commercial Manufacturing and Supply Agreement”) with Lonza Ltd (“Lonza”).”
Vaxcyte, Inc. amended 2023 Amendment with Sutro Biopharma, Inc. (effective 2023-09-28).
“Concurrent with the Companies’ mutual agreement upon the Form Definitive Agreement on September 28, 2023, the Companies entered into the 2023 Amendment.”
Vaxcyte, Inc. entered into Assignment and Assumption of Lease Agreement with Codexis, Inc. valued at initial monthly base rent of $5.85 per rentable square foot (approximately 36,593 rentable square fe (effective 2023-10-01).
“On September 1, 2023, Vaxcyte, Inc. (the “Company”) entered into an assignment and assumption of lease agreement (the “Assignment Agreement”) with Codexis, Inc. (the “Assignor”) for the purposes of expanding the Company’s headquarters located at 825 Industrial Road in San Carlos, California (the “Building”).”
Vaxcyte, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.”
Vaxcyte, Inc. shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers. at the 2023-06-13 meeting.
“3. The approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers. The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated: For Against Abstain Broker Non-Votes 62,915,437 7,157,815 54,191 4,802,816”
Vaxcyte, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
“2. The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain 74,913,275 3,583 13,401”
Vaxcyte, Inc. shareholders approved Election of three nominees to serve as Class III directors until the Company's 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. at the 2023-06-13 meeting.
“1. The election of three nominees to serve as Class III directors until the Company’s 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. The following three Class III directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Halley Gilbert, J.D. 61,216,757 8,910,686 4,802,816 Michael E. Kamarck, Ph.D. 69,655,830 471,613 4,802,816 Grant E. Pickering, M.B.A. 69,813,142 314,301 4,802,816”
Vaxcyte, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.”
Vaxcyte, Inc. entered into Master Services Agreement for Drug Substances and Microbial Products Development and Manufacturing with Lonza Ltd valued at Vaxcyte will pay Lonza for development and manufacturing services and pass-through expenses incurred (effective 2023-03-01).
“On February 28, 2023, Vaxcyte, Inc. (“ Vaxcyte ”) entered into a master services agreement for conjugated polysaccharide drug substances and microbial products development and manufacturing (the “ Master Services Agreement ”) with Lonza Ltd (“ Lonza ”), effective as of March 1, 2023 (the “ Effective Date ”), pursuant to which Lonza will perform manufacturing process development and the manufacture of components for VAX-24 and VAX-31 (formerly VAX-XP), including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.”
Vaxcyte, Inc. reported financial results for the quarter and full year ended December 31, 2022.
“On February 27, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2022.”
Vaxcyte, Inc. entered into Option Agreement with Sutro Biopharma, Inc. valued at $22.5 million (effective 2022-12-19).
“On December 19, 2022 (the “Effective Date”), Vaxcyte, Inc. (“Vaxcyte”) entered into an option grant agreement (the “Option Agreement”) with Sutro Biopharma, Inc. (“Sutro,” and together with Vaxcyte, the “Companies”),”
Elvia Cowan was appointed as Principal Accounting Officer at Vaxcyte, Inc..
“On December 6, 2022, the Board of Directors of Vaxcyte, Inc. (the “Company”) appointed Elvia Cowan, its Senior Vice President, Finance, as the Company’s principal accounting officer, effective January 1, 2023.”
Vaxcyte, Inc. reported financial results for third quarter ended September 30, 2022.
“On November 7, 2022, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Teri Loxam was appointed as Director at Vaxcyte, Inc..
“On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.”
Annie Drapeau was appointed as Director at Vaxcyte, Inc..
“On September 16, 2021, upon recommendation of the Nominating Committee, the Board appointed Annie Drapeau and Teri Loxam to the Board as Class I directors, which appointments became effective on September 16, 2021.”
Rob Hopfner resigned as Director at Vaxcyte, Inc..
“On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.”
Patrick Heron resigned as Director at Vaxcyte, Inc..
“On September 16, 2021, Patrick Heron, a director of the Vaxcyte, Inc. (the “Company”) and member of the Audit Committee, and Rob Hopfner, a director of the Company and member of the Nominating and Corporate Governance Committee (the “Nominating Committee”), both resigned as members of the Company’s Board of Directors (the “Board”), which resignations became effective on September 16, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.